IRVINE, Calif., Sept. 12, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that the Journal of Vascular Surgery Venous and Lymphatic Disorders published an article on present and future options for treating deep vein disease, which features the company’s VenoValve® implant. The Journal of Vascular Surgery Venous and Lymphatic Disorders is the official peer-reviewed journal of the Society for Vascular Surgery and the American Venous Forum. HJLI expects to begin first-in-human testing of the VenoValve in late 2018.
The article titled “Present and Future Options for Treatment of Infrainguinal Deep Vein Disease” addresses post thrombotic syndrome, a disease that occurs when a blood clot in the deep venous system creates chronic venous obstruction, reflux, or a combination of both, a condition that afflicts approximately 4.5 million people in the United States alone. The article focuses on the limitations doctors currently face in their ability to treat post thrombotic syndrome through existing measures, such as compression stockings and leg elevation. The article goes on to describe thrombotic syndrome as an “area of intense interest” among the vascular community and as “the final frontier in venous disease.” The article highlights HJLI’s VenoValve as a potentially curative treatment for venous reflux, a large and unmet medical need.
“We are thrilled to receive this acknowledgement in what is widely recognized as the world’s premier journal for vascular surgery,” said Robert Berman, Hancock Jaffe’s Chief Executive Officer. “The article supports our thesis that the VenoValve® is a potentially transformative technology that has the potential to drastically improve the lives of millions of patients that suffer from chronic venous insufficiency, and that the vascular community has taken notice of the VenoValve.”
HJLI is in the process of finalizing the necessary materials to submit to INVIMA, the Colombian equivalent of the U.S. Food and Drug Administration. INVIMA approval is the last regulatory hurdle to be cleared before the company can start its first-in-human trial, which it expects to begin in December of 2018.
The Journal of Vascular Surgery: Venous and Lymphatic Disorders is the premier international Journal of medical, endovascular and surgical management of venous and lymphatic disorders. The Journal provides novel and timely information to vascular surgeons, interventionalists, phlebologists, wound care specialists, and allied health professionals who treat patients presenting with venous and lymphatic disease. The Journal publishes high quality clinical, and laboratory research papers, case series, reviews, guidelines, techniques, and practice manuscripts related to all aspects of venous, lymphatic disease, and wound care with an emphasis on the practicing clinician. The article was published in the September 2018 edition of the Journal and is available for purchase at the JVSVenous.org website: https://www.jvsvenous.org/article/S2213-333X(18)30120-3/fulltext.
About Hancock Jaffe Laboratories, Inc.
HJLI specializes in developing and manufacturing bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has three product candidates: the porcine tissue based VenoValve®, which is intended to be surgically implanted in the deep venous system of the leg to treat Chronic Venue Insufficiency; the CoreoGraft®, a bovine tissue based off the shelf conduit intended to be used for coronary artery bypass surgery, and a porcine tissue based heart valve, which based upon its relatively small size and increased output, is an ideal candidate for pediatric aortic/mitral valve replacement.
HJLI Press Contacts: